2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
December 14, 2017BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia (CIN)Printer Friendly Version
December 7, 2017BeyondSpring to Webcast Key Opinion Leader Event in NYC on Dec. 14, 2017Printer Friendly Version
December 4, 2017BeyondSpring’s Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in ChinaPrinter Friendly Version
November 30, 2017BeyondSpring Initiates Global Phase 2/3 Trial with Plinabulin in China for the Prevention of Chemotherapy-Induced Neutropenia to Demonstrate SuperiorityPrinter Friendly Version
November 9, 2017BeyondSpring Reports Third Quarter 2017 Operational and Financial ResultsPrinter Friendly Version
November 2, 2017BeyondSpring to Host Quarterly Operational Update Conference Call on November 9, 2017Printer Friendly Version
October 26, 2017BeyondSpring Announces the First Patient Enrolled in China in its Global Phase 2/3 Trial with Plinabulin for the Prevention of Chemotherapy-Induced NeutropeniaPrinter Friendly Version
October 23, 2017BeyondSpring Receives Two Grants in China to Further Develop Innovative Drug PipelinePrinter Friendly Version
October 18, 2017BeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18 in San FranciscoPrinter Friendly Version
September 5, 2017BeyondSpring to Present at the 19th Annual Rodman & Renshaw Global Investment ConferencePrinter Friendly Version
August 21, 2017BeyondSpring Provides Operational Update for Second Quarter of 2017Printer Friendly Version
August 17, 2017BeyondSpring to Present at the 2017 Southern California Investor ConferencePrinter Friendly Version
August 14, 2017BeyondSpring to Host Quarterly Operational Update Conference Call on August 21, 2017Printer Friendly Version
July 6, 2017China FDA Approves CTAs for BeyondSpring’s Second Global Plinabulin Registrational Trial for Chemotherapy-Induced Neutropenia PreventionPrinter Friendly Version
June 15, 2017BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin at 2017 BIO International Convention in San DiegoPrinter Friendly Version
June 2, 2017BeyondSpring to Present at the Jefferies 2017 Healthcare ConferencePrinter Friendly Version
June 1, 2017BeyondSpring to Attend Jefferies 2017 Healthcare ConferencePrinter Friendly Version
May 22, 2017BeyondSpring Reports First Quarter 2017 Financial ResultsPrinter Friendly Version
May 8, 2017BeyondSpring Chief Medical Officer to Present at Three Prominent Industry Conferences in May 2017Printer Friendly Version
May 1, 2017BeyondSpring Files Its 2016 Annual Report on Form 20-FPrinter Friendly Version
April 28, 2017BeyondSpring Provides Quarterly Operational Update and Full Year 2016 ResultsPrinter Friendly Version
April 26, 2017BeyondSpring to Participate in Joseph Gunnar’s Pioneers 2017 Conference on May 2 in New YorkPrinter Friendly Version
April 25, 2017BeyondSpring Enrolls First U.S. Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia PreventionPrinter Friendly Version
April 13, 2017BeyondSpring to Host Quarterly Operational Update Conference Call on April 28, 2017Printer Friendly Version
March 22, 2017BeyondSpring Chief Medical Officer to Present on Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Prevention at BIO-Europe Spring 2017Printer Friendly Version
March 20, 2017BeyondSpring Lead Asset Plinabulin's Anti-Cancer Mechanism Accepted for Poster Presentation at the 2017 Keystone Symposia in British ColumbiaPrinter Friendly Version
March 14, 2017BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in TokyoPrinter Friendly Version
March 9, 2017Nasdaq Welcomes BeyondSpring Inc. (Nasdaq: BYSI) to The Nasdaq Stock MarketPrinter Friendly Version
March 9, 2017BeyondSpring Inc. Prices Initial Public Offering and Concurrent Private Placement of $54.31 MPrinter Friendly Version
February 21, 2017BeyondSpring’s Promising Clinical Data for Lead Asset on Non-Small Cell Lung Cancer Treatment Selected for Presentation at 2017 ASCO-SITC Clinical Immuno-Oncology SymposiumPrinter Friendly Version
January 24, 2017FDA Accepts BeyondSpring IND Application for Plinabulin for the Prevention of Chemotherapy-Induced NeutropeniaPrinter Friendly Version
January 10, 2017BeyondSpring Inc. to Present at Biotech Showcase 2017 During Annual JPMorgan Healthcare Conference on January 10 in San FranciscoPrinter Friendly Version
Print Page Print Page | Email Page Email Page | RSS Feeds RSS Feeds | Email Alerts Email Alerts | IR Contacts Contact IR | Financial Tear Sheet Financial Tear Sheet